CD33 and neoplasm: In another example, an anti-CD33 x anti-CD3 BsAb could successfully redirect cytotoxic T cells to acute myeloid leukemia (AML) cells leading to efficient killing of residual AML cells which frequently go unaffected by standard therapies and often lead to tumor relapse36.